Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT163 Vaccine for Genital Herpes Simplex Type 2
NCT05432583Phase 1Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Dec 2022
- Primary completion
- Oct 2026
- Modality
- Viral Vector Vaccines, Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BNT163 in Genital Herpes Type 2 (HSV-2) (6 arms), sponsored by BioNTech SE. Primary endpoints: Frequency of solicited local reactions at the injection site, Frequency of solicited systemic reactions and 4 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
BNT163
03
Conditions
Genital Herpes Type 2 (HSV-2)
Beyond the preview
Go deeper on NCT05432583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432583.